NO20033372L - Endotoksinbinding ved melkesyrebakterier og bifidobakterier - Google Patents

Endotoksinbinding ved melkesyrebakterier og bifidobakterier

Info

Publication number
NO20033372L
NO20033372L NO20033372A NO20033372A NO20033372L NO 20033372 L NO20033372 L NO 20033372L NO 20033372 A NO20033372 A NO 20033372A NO 20033372 A NO20033372 A NO 20033372A NO 20033372 L NO20033372 L NO 20033372L
Authority
NO
Norway
Prior art keywords
bifidobacteria
lactic acid
acid bacteria
endotoxin binding
endotoxin
Prior art date
Application number
NO20033372A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033372D0 (no
Inventor
Eduardo Schiffrin
Guillermo Kociubinski
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8179863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20033372(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of NO20033372D0 publication Critical patent/NO20033372D0/no
Publication of NO20033372L publication Critical patent/NO20033372L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/854—Lactobacillus acidophilus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
NO20033372A 2001-02-06 2003-07-28 Endotoksinbinding ved melkesyrebakterier og bifidobakterier NO20033372L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01200436 2001-02-06
PCT/EP2002/001163 WO2002062360A1 (en) 2001-02-06 2002-02-01 Endotoxin binding by lactic acid bacteria and bifidobacteria

Publications (2)

Publication Number Publication Date
NO20033372D0 NO20033372D0 (no) 2003-07-28
NO20033372L true NO20033372L (no) 2003-07-28

Family

ID=8179863

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033372A NO20033372L (no) 2001-02-06 2003-07-28 Endotoksinbinding ved melkesyrebakterier og bifidobakterier

Country Status (21)

Country Link
US (2) US7550285B2 (es)
EP (1) EP1359924B1 (es)
JP (3) JP2004531477A (es)
KR (1) KR100845456B1 (es)
CN (1) CN1250232C (es)
AT (1) ATE375164T1 (es)
AU (1) AU2002250886B2 (es)
BR (1) BR0207019A (es)
CA (1) CA2436264C (es)
DE (1) DE60222856T2 (es)
EA (1) EA006397B1 (es)
ES (1) ES2292744T3 (es)
HK (1) HK1066174A1 (es)
IL (1) IL157071A0 (es)
MX (1) MXPA03007024A (es)
NO (1) NO20033372L (es)
NZ (1) NZ527493A (es)
PL (1) PL367083A1 (es)
PT (1) PT1359924E (es)
WO (1) WO2002062360A1 (es)
ZA (1) ZA200306935B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527493A (en) * 2001-02-06 2005-06-24 Nestle Sa Endotoxin binding by lactobacillus and bifidobacteria having hydrophobic surface properties and use of the bacteria in treating endotoxin ( LPS ) mediated disorders
US7179460B2 (en) * 2002-12-05 2007-02-20 Danisco A/S Bacterial composition and its use
SE526711C2 (sv) 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
PL1885383T3 (pl) 2005-05-31 2017-06-30 Iams Europe B.V. Kocie probiotyczne bifidobakterie
AU2006253006B8 (en) 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
US20090083067A1 (en) * 2006-03-29 2009-03-26 Mary Elaine Freeland Methods and kits for selecting a health care product
PL2124966T3 (pl) 2007-02-01 2016-01-29 Iams Europe B V Sposób zmniejszania reakcji zapalnej i stresu u ssaków za pomocą antymetabolitów glukozy, awokado lub ekstraktów awokado
EP2114423B2 (en) * 2007-02-28 2020-01-01 MJN U.S. Holdings LLC Inactivated lactobacillus rhammosus gg for treating systemic inflammation in infants
KR100913406B1 (ko) * 2008-03-25 2009-08-21 광주과학기술원 Ｔｈ１－매개 면역 질환의 예방 또는 치료용 조성물
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
PL2459203T3 (pl) * 2009-07-30 2019-04-30 Dupont Nutrition Biosci Aps Bakterie kwasu mlekowego i bifidobakterie do leczenia endotoksemii
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
WO2011069860A1 (en) 2009-12-08 2011-06-16 Chr. Hansen A/S Novel use for the treatment of metabolic endotoxemia
JP2010280664A (ja) * 2010-07-02 2010-12-16 Biogaia Ab ラクトバチルス・リューテリ（Ｌａｃｔｏｂａｃｉｌｌｕｓｒｅｕｔｅｒｉ）株を用いる哺乳類における免疫機能の改善方法
US20140234487A1 (en) 2011-07-13 2014-08-21 Friesland Brands B.V. Dairy based compositions with low lps
US20130022586A1 (en) * 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
US9173910B2 (en) 2012-02-29 2015-11-03 The General Hospital Corporation Compositions of microbiota and methods related thereto
AU2014324694B2 (en) * 2013-09-30 2017-06-29 Elc Management Llc Watery lotion skin care compositions and methods
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
CN104498375B (zh) * 2014-12-02 2017-05-10 江南大学 一株具有内毒素吸附特性的耶氏酵母及其吸附特性研究方法
JP6710075B2 (ja) * 2016-03-29 2020-06-17 カゴメ株式会社 Ｌｐｓ産生抑制剤、及びｌｐｓ産生抑制用の食品組成物
TWI640319B (zh) * 2017-05-12 2018-11-11 健茂生物科技股份有限公司 具有抗發炎活性之醱酵液的製備方法
AU2018326705A1 (en) 2017-08-30 2020-03-05 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
JP6888145B2 (ja) * 2020-03-23 2021-06-16 カゴメ株式会社 Ｌｐｓ産生抑制剤、及びｌｐｓ産生抑制用の食品組成物
WO2021253017A2 (en) * 2020-06-07 2021-12-16 Ramasamy Sundaram Compositions and methods for detoxifying bacterial endotoxins and hydrogen sulfide by recombinant fusion enzymes
WO2022043223A1 (en) 2020-08-28 2022-03-03 Chr. Hansen A/S Microencapsulation of microbial culture using octenyl succinic anhydride starch-chitosan complex coacervate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US555618A (en) * 1896-03-03 Hay-loader
IT1254210B (it) 1992-02-10 1995-09-14 Simone Claudio De Composizioni dietetiche e/o farmaceutiche a base di batteri lattici liofilizzati, loro preparazione e impiego
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
JP2506314B2 (ja) * 1993-10-27 1996-06-12 全国農業協同組合連合会 家禽・豚の敗血症の予防・治療剤及び飼料
US6506389B2 (en) * 1995-10-20 2003-01-14 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek (Tno) Adherence factors of non pathogenic microorganisms and applications thereof for screening microorganisms for specific probiotic properties; novel pharmaceutical compositions and food additives comprising such microorganisms and adherence factors
DE29724815U1 (de) * 1997-01-09 2004-07-22 Société des Produits Nestlé S.A. Probiotik enthaltendes Getreideprodukt
JP4163276B2 (ja) * 1998-02-05 2008-10-08 独立行政法人理化学研究所 機能性組成物
US6368591B2 (en) * 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
WO2000035465A2 (en) * 1998-12-11 2000-06-22 Urex Biotech Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
EP1276488B1 (en) * 2000-03-24 2006-12-20 Societe Des Produits Nestle S.A. Use of lactic acid bacterium for the prevention of peritonitis
NZ527493A (en) * 2001-02-06 2005-06-24 Nestle Sa Endotoxin binding by lactobacillus and bifidobacteria having hydrophobic surface properties and use of the bacteria in treating endotoxin ( LPS ) mediated disorders

Also Published As

Publication number Publication date
EA200300862A1 (ru) 2003-12-25
MXPA03007024A (es) 2003-11-18
PT1359924E (pt) 2007-12-07
EP1359924A1 (en) 2003-11-12
BR0207019A (pt) 2004-02-25
US20040115178A1 (en) 2004-06-17
ATE375164T1 (de) 2007-10-15
JP2004531477A (ja) 2004-10-14
NO20033372D0 (no) 2003-07-28
ZA200306935B (en) 2004-12-06
EA006397B1 (ru) 2005-12-29
EP1359924B1 (en) 2007-10-10
US7964384B2 (en) 2011-06-21
CN1250232C (zh) 2006-04-12
WO2002062360A1 (en) 2002-08-15
ES2292744T3 (es) 2008-03-16
DE60222856D1 (de) 2007-11-22
HK1066174A1 (en) 2005-03-18
CN1501805A (zh) 2004-06-02
US7550285B2 (en) 2009-06-23
NZ527493A (en) 2005-06-24
KR100845456B1 (ko) 2008-07-10
US20100136662A1 (en) 2010-06-03
IL157071A0 (en) 2004-02-08
JP5973701B2 (ja) 2016-08-23
KR20030076652A (ko) 2003-09-26
JP2014062104A (ja) 2014-04-10
CA2436264C (en) 2014-01-28
CA2436264A1 (en) 2002-08-15
JP2011246483A (ja) 2011-12-08
PL367083A1 (en) 2005-02-21
DE60222856T2 (de) 2008-07-24
AU2002250886B2 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
NO20033372D0 (no) Endotoksinbinding ved melkesyrebakterier og bifidobakterier
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2348036A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
IL147271A0 (en) Compounds that bind her2
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
IL195142A (en) Processed arylaimidazolone and triazolone, their preparation process, pharmaceutical preparations containing them for the treatment or prevention of diseases
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2003099110A3 (en) Herbs and herbal combinations useful for the treatment of microbial infections
WO2006082328A3 (fr) Compositions comprenant des micro-organismes deshydrates, leurs procedes de preparation, et leurs utilisations
WO2006034001A3 (en) Methods of treating hiv infection
WO2007030708A3 (en) Antimicrobial adzymes and uses thereof
IL141325A0 (en) Tan-1057 derivatives
BRPI0409609A (pt) mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia
DE60235418D1 (de) Osteoprotegerin in Milch
WO2022106897A3 (en) Methods and composition for kras modifications
WO2009057282A1 (ja) 骨吸収抑制用食品素材
WO2003026693A3 (en) Inhibitors of costimulation by 0x40 and their use against infectious diseases
WO2007058934A3 (en) Methods and compositions for treating basement membrane disorders
EP1631298B8 (en) Glycosaminoglycans for treating emotional dysfunctions
WO2007007362A3 (en) Vegf-d and functional fragments thereof for bone repair
WO2006069911A3 (en) Mucoadhesive pharmaceutical compositions comprising chemoattractants
WO2003053959A8 (de) Heterocyclylaminocarbo nyluracile

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application